# Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period

> **NCT03714373** · PHASE3 · COMPLETED · sponsor: **Soleno Therapeutics, Inc.** · enrollment: 115 (actual)

## Conditions studied

- Prader-Willi Syndrome

## Interventions

- **DRUG:** DCCR
- **DRUG:** DCCR
- **DRUG:** Placebo for DCCR

## Key facts

- **NCT ID:** NCT03714373
- **Lead sponsor:** Soleno Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-01
- **Primary completion:** 2023-08-17
- **Final completion:** 2023-08-17
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03714373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03714373, "Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03714373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*